Viewing nowValsartan 80 mg Tablet
Valsartan 80mg
Tablet · Prescription medication
Kyungdong Pharmaceutical Co., Ltd.

MFDS item code 201104754 · Notified 2011.07.28 · Insurance code 648103090
Treatment of hypertension, reduction of the risk of death after myocardial infarction, and treatment of heart failure
This medication primarily helps control blood pressure in patients with essential hypertension and is also used in heart failure patients who are intolerant to ACE inhibitors (NYHA class II to IV). It is effective in reducing the risk of death in stable patients with left ventricular dysfunction or impaired contractility after a myocardial infarction. Thus, it is used for hypertension, heart failure, and prevention of complications after myocardial infarction.
1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect appears gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg per day or a diuretic may be co-administered. If additional blood pressure reduction is needed, the dose may be increased up to a maximum of 320 mg per day. 2) Elderly patients (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg per day. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When co-administering a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily; over the following weeks, increase the dose according to patient tolerability to 40 mg, 80 mg, and 160 mg per dose, administered twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, co-administration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required when creatinine clearance is 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
The safety and efficacy have not been established in pediatric patients and adolescents under 18 years. The safety and efficacy have not been established in pediatric patients and adolescents under 18 years.
This medication can cause serious harm to the fetus if used during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Women who are pregnant, may become pregnant, or are breastfeeding should not take this medication. It is also unsafe to administer this drug to patients with severely impaired liver function, liver cirrhosis, or cholestasis. Patients with hereditary angioedema or a history of angioedema, as well as those with severe renal impairment, should not use this medication. Diabetic patients with reduced renal function should avoid taking this medication with specific drugs, and elderly patients, those with high serum potassium levels, and those with liver dysfunction should use this medication cautiously. Blood pressure may drop sharply during treatment, so it is important to monitor the patient's condition carefully when starting the medication or increasing the dose. Patients undergoing dialysis or taking diuretics, as well as those with strict sodium restrictions, are at a higher risk of hypotension and should be cautious. There may be interactions when taking this medication with other antihypertensive drugs, diuretics, potassium supplements, etc., so consult with a physician or pharmacist. It is important to regularly monitor renal function and serum potassium levels through blood tests, and to inform medical staff immediately if any abnormal symptoms occur. This medication is not recommended for use in children and adolescents since its safety and efficacy have not been established. In the case of an overdose, severe hypotension or decreased consciousness may occur, so it is essential to seek medical attention immediately.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to prevent air or moisture from entering. Additionally, it is important to store it in a cool place below 30 degrees Celsius to maintain the efficacy of the drug.
Bright pink round film-coated tablet with a split line on one side
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 80mg
Tablet · Prescription medication
Kyungdong Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.